U.S. FDA

FDA Grand Rounds: Clinical Omics Biomarker Discovery and Validation in Precision Medicine

The FDA Grand Rounds session featured Dr. Richard Beger discussing clinical omics biomarker discovery and validation for precision‑medicine applications. He outlined the breadth of systems‑biology omics—genomics, transcriptomics, proteomics, metabolomics, lipidomics—and described a structured workflow that stresses early sample‑type decisions, rigorous quality control, and iterative bioinformatic modeling. Key insights included the translation of non‑clinical metabolomics and microRNA data into clinical settings, illustrated by early elevation of long‑chain acylcarnitines as a mitochondrial toxicity signal in acetaminophen overdose. Additional case studies covered proteomic signatures that forecast kidney recovery after dialysis‑dependent acute kidney injury, baseline cardiotoxic proteomics predicting doxorubicin‑induced heart injury, and a novel method pairing microRNA‑protein markers to gauge respiratory disease severity. Notable examples highlighted palmitoylcarnitine’s consistent rise across mouse, rat, and human studies, microRNA‑122 as a liver injury indicator, and the development of targeted LC‑MS assays that bridge open‑profiling discovery to clinical quantification. Dr. Beger emphasized the importance of multi‑omics integration to capture pre‑injury, injury, and recovery phases, enabling more nuanced phenotypic definitions. The implications are clear: standardized, multi‑omics pipelines can accelerate biomarker qualification, support FDA regulatory frameworks, and empower clinicians to personalize therapy based on early, mechanistic signals rather than downstream clinical outcomes.